H
Hendrik Schulze-Koops
Researcher at Ludwig Maximilian University of Munich
Publications - 373
Citations - 11710
Hendrik Schulze-Koops is an academic researcher from Ludwig Maximilian University of Munich. The author has contributed to research in topics: Rheumatoid arthritis & Medicine. The author has an hindex of 49, co-authored 335 publications receiving 9513 citations. Previous affiliations of Hendrik Schulze-Koops include Max Planck Society & University of Erlangen-Nuremberg.
Papers
More filters
Journal ArticleDOI
Trial of Tocilizumab in Giant-Cell Arteritis.
John H. Stone,Katie Tuckwell,Sophie Dimonaco,Micki Klearman,Martin Aringer,Daniel Engelbert Blockmans,Elisabeth Brouwer,Maria C. Cid,Bhaskar Dasgupta,Juergen Rech,Carlo Salvarani,Georg Schett,Hendrik Schulze-Koops,Robert Spiera,Sebastian Unizony,Neil Collinson +15 more
TL;DR: Tocilizumab, received weekly or every other week, combined with a 26‐week prednisone taper was superior to either 26‐ week or 52‐weekprednisone tapering plus placebo with regard to sustained glucocorticoid‐free remission in patients with giant‐cell arteritis.
Journal ArticleDOI
Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
Roy Fleischmann,Joel M. Kremer,John J. Cush,Hendrik Schulze-Koops,Carol A. Connell,John D. Bradley,David Gruben,Gene V. Wallenstein,Samuel H. Zwillich,Keith S. Kanik +9 more
TL;DR: In patients with active rheumatoid arthritis, tofacitinib monotherapy was associated with reductions in signs and symptoms of rheumatism and improvement in physical function and tofacit inib treatment wasassociated with elevations in low-density lipoprotein cholesterol levels and reductions in neutrophil counts.
Journal ArticleDOI
Role of Th17 cells in human autoimmune arthritis
Jan Leipe,Mathias Grunke,Claudia Dechant,C. Reindl,Ulrike Kerzendorf,Hendrik Schulze-Koops,Alla Skapenko +6 more
TL;DR: The intrinsically elevated expression of RORC, accompanied by biased Th17 cell development, and the resistance of Th17 cells to a natural cytokine antagonist in patients with RA and patients with PsA were suggestive of the underlying molecular mechanisms of uncontrolled Th17 activity in these patients.
Journal ArticleDOI
Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial
Iain B. McInnes,Joachim Sieper,Juergen Braun,Paul Emery,Désirée van der Heijde,John D. Isaacs,Georg Dahmen,Jürgen Wollenhaupt,Hendrik Schulze-Koops,Joseph Kogan,Shenglin Ma,Martin Schumacher,Arthur P. Bertolino,Wolfgang Hueber,Paul P. Tak,Paul P. Tak +15 more
TL;DR: Although the primary endpoint was not met, clinical responses, acute-phase reactant and quality of life improvements were greater with secukinumab versus placebo, suggesting some clinical benefit.